Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Opening Session Panel Discussion

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Jan

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Opening Session Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Study Explores Association of GLP-1 RAs With Risk of Obesity-Related Cancers

Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL

Deb Schrag Elected 2027–2028 ASCO President

NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer

Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns